BridgeBio Pharma, Inc.BBIO

時価総額

$145.3億

PER

遺伝性疾患治療薬の研究開発の新興企業。治療候補のAttrubyやBeyonttraを展開。2024年1月の資金提供契約でFDA承認時に5億ドル受領見込み、2024年3月の公募で約2.77億ドルを調達。米国・欧州中心に展開。

	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-289	-505	-586	-485	-653	-543
Stock-based compensation	21	58	100	92	109	96
Loss on extinguishment of debt	-	-	-3	-	-	-27
Accretion of debt	2	18	6	9	9	16
Depreciation and amortization	-	-	6	7	6	6
Noncash lease expense	-	-	6	5	4	4
Accrual of payment-in-kind interest on term loan	-	-	-	14	10	-
Net loss from equity method investments	-21	-	-	-	-	-31
Loss (gain) on deconsolidation of subsidiaries	-	-	-	-	-1	178
Loss (gain) from investment in equity securities, net	-	-	30	-8	18	8
Fair Value Of Shares Issued Under License Agreements	-	6	-	5	-	-
Loss on sale of certain assets	-	-	-	-6	-	-
Impairment of long-lived assets	-	-	-	13	-	0
Gain from sale of priority review voucher, excluding transaction costs	-	-	-	110	-	-
Gain from recognition of receivable from licensing and collaboration agreement	-	-	-	13	-	-
Other noncash adjustments, net	-1	-3	-7	-1	-0	3
Accounts receivable	-	-	-	-	-	3
Receivables from licensing and collaboration agreements	-	-	20	-15	-15	-
Prepaid expenses and other current assets	13	7	4	-8	3	14
Other assets	17	2	10	-11	2	-2
Accounts payable	-5	-1	3	-0	3	2
Accrued compensation and benefits	9	9	7	-2	8	17
Accrued research and development liabilities	12	6	11	-4	-10	9
Operating lease liabilities	-	-	-6	-6	-5	-6
Deferred revenue	-	-	-	15	-5	22
Accrued professional and other liabilities	2	8	12	-3	4	4
Net cash used in operating activities	-254	-400	-498	-419	-528	-521
Purchases of marketable securities	213	288	590	137	30	94
Maturities of marketable securities	-	249	380	480	83	95
Purchases of investments in equity securities	-	-	-	56	108	20
Proceeds from Sale of Equity Securities, FV-NI	-	-	-	53	111	63
Proceeds from Equity Method Investment, Distribution, Return of Capital	-	-	-	-	-	26
Payment for an intangible asset	-	-	35	2	-	8
Proceeds from sale of certain assets	-	-	-	10	-	-
Purchases of property and equipment	3	8	13	5	1	1
Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries	-	-	-	-	1	0
Net cash provided by investing activities	-217	-53	-201	453	54	61
Proceeds from royalty obligation under Funding Agreement	-	-	-	-	-	500
Issuance costs and discounts associated with royalty obligation under Funding Agreement	-	-	-	-	-	28
Proceeds from Debt, Net of Issuance Costs	37	-	456	-	-	450
Issuance costs and discounts associated with term loan under Amended Financing Agreement	-	13	16	-	-	16
Repayment of term loans	-	-	124	20	-	473
Proceeds from Issuance of Common Stock	-	-	-	5	144	315
Proceeds from Stock Plans	1	1	4	3	3	5
Proceeds from Stock Options Exercised	2	13	17	1	6	4
Transactions with noncontrolling interests	-	-	-	-	-1	-
Repurchase of RSU shares to satisfy tax withholding	-	1	5	2	7	8
Other financing activities	-	-	-	1	-	-
Net cash provided by (used in) financing activities	399	447	736	-13	452	748
Net increase (decrease) in cash, cash equivalents and restricted cash	-72	-6	38	21	-22	289
Cash paid for interest	6	15	30	54	61	91
Unpaid property and equipment	-	1	1	0	0	0
Transfers to noncontrolling interests	-29	12	-2	-4	-11	-6
Payment-in-kind interest added to principal of term loan	-	-	-	2	-	-